Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 25 Equity-to-Asset is 0.78 as of Mar. 2026, which is 8% below its 10-year median of 0.85. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Molecular Partners AG ranks better than 62.29% on this metric.
The historical rank and industry rank for Molecular Partners AG's Equity-to-Asset or its related term are showing as below:
MLLCF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42 Med: 0.85 Max: 0.91
Current: 0.78
During the past 13 years, the highest Equity to Asset Ratio of Molecular Partners AG was 0.91. The lowest was 0.42. And the median was 0.85.
MLLCF's Equity-to-Asset is ranked better than 62.29% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs MLLCF: 0.78
Molecular Partners AG (OTCPK:MLLCF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Molecular Partners AG Equity-to-Asset Related Terms
Molecular Partners AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Molecular Partners AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Molecular Partners AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Equity-to-Asset of 0.78 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Molecular Partners AG and its competitors. This is near median its historical median of 0.85. Over the past decade, Molecular Partners AG's Equity-to-Asset has ranged from 0.42 to 0.91. According to the industry distribution chart, Molecular Partners AG ranks #534 out of 1416 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Molecular Partners AG's Equity-to-Asset too high?
Molecular Partners AG's current Equity-to-Asset of 0.78 is near median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 0.91. The Biotechnology industry median Equity-to-Asset is 0.68. Molecular Partners AG's value of 0.78 is 14.7% above this industry median. Based on the distribution chart, Molecular Partners AG ranks #534 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #534 out of 1416 companies for Equity-to-Asset. This puts Molecular Partners AG in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Molecular Partners AG's value of 0.78 is 14.7% above this benchmark. Historically, Molecular Partners AG's own Equity-to-Asset has ranged from 0.42 to 0.91 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.68, Molecular Partners AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Equity-to-Asset of 0.78 is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Equity-to-Asset is 0.78, which is near median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $3.80 — trading 763.6% above its estimated fair value. The current Equity-to-Asset is 0.78, which is near median its 10-year median of 0.85 and 14.7% above the Biotechnology industry median of 0.68. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Equity-to-Asset is 0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.80 is trading 763.6% above its estimated GF Value™ of $0.44.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Equity-to-Asset: 0.78 (near median its 10-year median of 0.85)
GF Value™: $0.44 vs. price of $3.80 (763.6% above fair value)
Industry Position: 14.7% above the Biotechnology median (#534 of 1416)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
